Nuevolution, Boehringer collaborate in drug discovery

Tuesday, September 20, 2011 12:22 PM

Nuevolution has entered into a collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics drug discovery technology.

Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim.

The Chemetics platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming both small molecules and synthetic biologics. In its existing collaborations, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.

Boehringer Ingelheim will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs